Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding

JAAD Case Reports

Volumn 3, Issue 2, 2017, Pages 90-92

  Yin, Emily S ^a   Totonchy, Mariam B ^a   Leventhal, Jonathan S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adverse events; immunomodulators; immunotherapy; nivolumab; programmed cell death 1; vitiligo

Indexed keywords

NIVOLUMAB;

ACUTE MYELOID LEUKEMIA; ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; DEPIGMENTATION; HUMAN; MALE; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PURPURA; RASH; VITILIGO;

EID: 85014364501     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2016.10.008     Document Type: Article

References (7)

1. 1 National Cancer Institute. Bethesda, MD: National Institutes of Health. Nivolumab. Available from: http://www.cancer.gov/about-cancer/treatment/drugs/nivolumab. Published January 7, 2015. [Updated May 19, 2016. Cited August 25, 2016.].
2. 2 Goldinger, S.M., Stieger, P., Meier, B., et al. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. Clin Cancer Res 22:16 (2016), 4023–4029.
3. 3 Nakamura, Y., Tanaka, R., Asami, Y., et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol, 2016, 10.1111/1346-8138.13520.
4. 4 Ohtsuka, M., Miura, T., Mori, T., Ishikawa, M., Yamamoto, T., Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma. JAMA Dermatol 151:7 (2015), 797–799.
5. 5 Sibaud, V., Meyer, N., Lamant, L., Vigarios, E., Mazieres, J., Delord, J.P., Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28:4 (2016), 254–263.
6. 6 Houghton, A.N., Eisinger, M., Albino, A.P., Cairncross, J.G., Old, L.J., Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med 156:6 (1982), 1755–1766.
7. 7 Teulings, H.E., Limpens, J., Jansen, S.N., et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33:7 (2015), 773–781.